hVIVO PLC's (AIM:HVO) consultancy contract with Decoy Therapeutics, announced on Monday, is a small deal by any financial measure, but Peel Hunt's reading of it points to something more strategically significant for the AIM-listed contract research organisation. The agreement covers a wide range of services to support Decoy's development of its Designable Multi-Antiviral candidates, a novel antiviral category targeting shared mechanisms across multiple respiratory viruses with a single, adaptable therapeutic approach.